ArticleNature biotechnology2011
An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells.
Article in Nature biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
198 citing papers in PubMed, 1 synthesis or guideline pooled it, 373 citations in OpenAlex.
- Unravelling the pluripotency paradox in fetal and placental mesenchymal stem cells: Oct-4 expression and the case of The Emperor's New Clothes.Stem cell reviews and reports · 2013Pooled it
- Integrated Multi-Omics Analysis Uncovers Molecular Dysregulation in Glucosylceramide Synthase-Deficient Human Induced Pluripotent Stem Cells.Molecular & cellular proteomics : MCP · 2026Article
- Glycan-related genes and genetic disorders.Journal of human genetics · 2026Review
- Glycan Markers of Pluripotent Stem Cells.Advances in experimental medicine and biology · 2026Review
- Biological tendon regeneration, are we almost there or is it still a stretch?Regenerative medicine · 2025Article
- Elimination of tumorigenic pluripotent stem cells from their differentiated cell therapy products: An important step toward ensuring safe cell therapy.Stem cell reports · 2025Review
- EIF3D safeguards the homeostasis of key signaling pathways in human primed pluripotency.Science advances · 2025Article
- Glycosylation in Stem Cell Biology.Handbook of experimental pharmacology · 2025Review
- From stem cells to pancreatic β-cells: strategies, applications, and potential treatments for diabetes.Molecular and cellular biochemistry · 2025Review
- Terminal α1,2-fucosylation of glycosphingolipids by FUT1 is a key regulator in early cell-fate decisions.EMBO reports · 2024Article
- Progress in preclinical research on induced pluripotent stem cell therapy for acute myocardial infarction.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Review
- Label-Free and High-Throughput Removal of Residual Undifferentiated Cells From iPSC-Derived Spinal Cord Progenitor Cells.Stem cells translational medicine · 2024Article
- Glycan Modifications as Regulators of Stem Cell Fate.Biology · 2024Review
- Review
- A short history of pluripotent stem cells markers.Stem cell reports · 2024Review
- Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments.Biomedicines · 2023Review
- Targeting the stage-specific embryonic antigen (SSEA)-0 tumor neoantigen.Current trends in immunology · 2023Article
- Non-coding RNAs: key regulators of reprogramming, pluripotency, and cardiac cell specification with therapeutic perspective for heart regeneration.Cardiovascular research · 2022Review
- Optimizing Generation of Stem Cell-Derived Islet Cells.Stem cell reviews and reports · 2022Review
- Downstream bioprocessing of human pluripotent stem cell-derived therapeutics.Engineering in life sciences · 2022Review
138 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 1 institution in 2 countries.
Funding
Abstract
An important risk in the clinical application of human pluripotent stem cells (hPSCs), including human embryonic and induced pluripotent stem cells (hESCs and hiPSCs), is teratoma formation by residual undifferentiated cells. We raised a monoclonal antibody against hESCs, designated anti-stage-specific embryonic antigen (SSEA)-5, which binds a previously unidentified antigen highly and specifically expressed on hPSCs--the H type-1 glycan. Separation based on SSEA-5 expression through fluorescence-activated cell sorting (FACS) greatly reduced teratoma-formation potential of heterogeneously differentiated cultures. To ensure complete removal of teratoma-forming cells, we identified additional pluripotency surface markers (PSMs) exhibiting a large dynamic expression range during differentiation: CD9, CD30, CD50, CD90 and CD200. Immunohistochemistry studies of human fetal tissues and bioinformatics analysis of a microarray database revealed that concurrent expression of these markers is both common and specific to hPSCs. Immunodepletion with antibodies against SSEA-5 and two additional PSMs completely removed teratoma-formation potential from incompletely differentiated hESC cultures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.